Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;12(1):175-182.
doi: 10.1007/s40487-023-00257-0. Epub 2024 Jan 27.

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Reyes Bernabé  1 , Stephen V Liu  2 , Amparo Sánchez-Gastaldo  3 , Miriam Alonso García  3
Affiliations

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Reyes Bernabé et al. Oncol Ther. 2024 Mar.

Abstract

Survival beyond 2 years is rare in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemotherapy alone. We describe a patient with ES-SCLC who was treated with carboplatin, etoposide and the programmed death-ligand 1 inhibitor atezolizumab in the IMpower133 study (ClinicalTrials.gov registration: NCT02763579) and who achieved exceptionally long-term survival. Treatment-naïve patients with ES-SCLC (n = 403) were included in the IMpower133 study, and the identified patient had been randomised to the investigational treatment arm, where patients received induction therapy with carboplatin and etoposide plus atezolizumab for four 21-day cycles, followed by ongoing maintenance therapy with atezolizumab. The patient had achieved a partial response after induction therapy, and then received seven cycles of atezolizumab maintenance therapy until immune-related toxicities necessitated discontinuation. The patient was alive with an ongoing response and excellent performance status more than 6 years after starting treatment and 5 years after discontinuing atezolizumab maintenance. In conclusion, this patient with ES-SCLC from the IMpower133 study is a rare example of ongoing survival more than 6 years beyond diagnosis and the start of treatment with first-line atezolizumab. This demonstrates the potential durability of response with immunotherapy.

Keywords: Atezolizumab; Carboplatin; Etoposide; Long-term survival; Small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Stephen V. Liu has been on an advisory board for or acted as a consultant for AbbVie, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck/MSD, Merus, Novartis, Regeneron, Sanofi, Takeda and Turning Point Therapeutics and has received research funding (to institution) from Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Nuvalent, RAPT and Turning Point Therapeutics. Reyes Bernabé, Amparo Sánchez-Gastaldo and Miriam Alonso García declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Computed tomography images showing A mediastinal and right hilar adenopathy with multiple conglomerate masses involving the bronchus of the upper right lobe and surrounding the superior vena cava (27 October 2016), B partial response after induction therapy with four 21-day cycles of carboplatin + etoposide + atezolizumab (26 January 2017) and C continued partial response more than 5 years after stopping maintenance treatment (26 January 2023)
Fig. 2
Fig. 2
Immunohistochemical stains for A CD56 and B Ki-67
Fig. 3
Fig. 3
Bone gammagraphy image of the upper leg showing metastasis in the femur
Fig. 4
Fig. 4
Staining of tissue collected during a kidney biopsy performed in July 2017 (5 days after resuming atezolizumab maintenance treatment) showing immunotherapy-induced nephropathy
See this image and copyright information in PMC

References

    1. Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res. 2016;170:301–322. doi: 10.1007/978-3-319-40389-2_14. - DOI - PubMed
    1. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69–79. doi: 10.21037/tlcr.2018.01.16. - DOI - PMC - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–2229. doi: 10.1056/NEJMoa1809064. - DOI - PubMed
    1. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939. doi: 10.1016/S0140-6736(19)32222-6. - DOI - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: small cell lung cancer. Version 2.2022. 2021. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 10 Feb 2022. - PMC - PubMed

Associated data